Navigation Links
Synvista Therapeutics to be Featured on Wallst.net
Date:10/5/2007

MONTVALE, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer will be featured in an exclusive interview with Wallst.net on Monday, October 8, 2007 at 11:00 a.m. EDT.

Dr. Berkowitz will discuss the company's planned and/or ongoing Phase 2 initiatives for ALT-2074 in cardiovascular diseases, and alagebrium in heart failure and diabetic nephropathy. He will also provide an update of recent milestones and executive appointments.

The interview will be posted on http://www.wallst.net by 1:00 p.m. EDT. To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Innovation featured in NE Wisconsin Roundtable
3. Madison music featured on Internet radio station
4. Wisconsin biotech sector featured in scientific magazine
5. The Information Age of Healthcare - Leaders featured on local new economy show
6. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it ... and genetic testing lab equipment from two different leading institutes. This highly specialized laboratory ... of the United States. This 1-day online auction will take place on BidMed’s ...
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University City ... Pennsylvania Department of Community and Economic Development in 2016 as part of the Keystone ... University City Keystone Innovation Zone and represent the highest number of awards to the ...
(Date:1/18/2017)... 18, 2017  HUYA Bioscience International, (HUYA), the leader ... pharmaceutical innovations, announced today a strategic collaboration ... Investment Company (referred to as CAS Innovation). The collaboration ... by leading scientists at CAS to meet the medical ... is the first company to have recognized ...
(Date:1/18/2017)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) ... and commercializes proprietary technologies and products for advanced ... that Cameron Prange , President of Kingsdale ... Board of Directors.  Mr. Prange,s resignation is related ... limited both his ability to act on behalf ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):